Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection

Fred Poordad; William Sievert; Lindsay Mollison; Michael Bennett; Edmund Tse; Norbert Braeu; James Levin; Thomas Sepe; Samuel S Lee; Peter Angus; Brian Conway; Stanislas Pol; Nathalie Boyer; Jean-Pierre Bronowicki; Ira Jacobson; Andrew J Muir; K Rajender Reddy; Edward Tam; Grisell Ortiz-Lasanta; Victor de Ledinghen; Mark Sulkowski; Navdeep Boparai; Fiona McPhee; Eric Hughes; E Scott Swenson; Philip D Yin

Journal article

Fixed-Dose Combination Therapy With Daclatasvir, Asunaprevir, and Beclabuvir for Noncirrhotic Patients With HCV Genotype 1 Infection

Fred Poordad, William Sievert, Lindsay Mollison, Michael Bennett, Edmund Tse, Norbert Braeu, James Levin, Thomas Sepe, Samuel S Lee, Peter Angus, Brian Conway, Stanislas Pol, Nathalie Boyer, Jean-Pierre Bronowicki, Ira Jacobson, Andrew J Muir, K Rajender Reddy, Edward Tam, Grisell Ortiz-Lasanta, Victor de Ledinghen Show all

JAMA | AMER MEDICAL ASSOC | Published : 2015

DOI: 10.1001/jama.2015.3860

University of Melbourne Researchers

Peter Angus Author Medicine - Austin Health

Grants

Funding Acknowledgements

This study was funded by Bristol-Myers Squibb. Editorial support was provided by Andrew Street, PhD, of Articulate Science and was funded by Bristol-Myers Squibb.